International Journal of Clinical Research

Objective To investigate the clinical effect of dulaglutide combined with metformin in the treatment of obese type 2 diabetes. Methods 100 obese type 2 diabetes patients admitted from March 2022 to March 2024 were selected as research objects and randomly divided into the control group (50 cases, treated with metformin) and the observation group (50 cases, treated with dulaglutide combined with metformin). Compare the blood glucose indicators (fasting blood glucose (FBG), 2-hour postprandial blood glucose (2-hour PBG)), body mass index (BMI), and quality of life between two groups of patients. Results The levels of FBG, 2-hour PBG, and BMI in the observation group were lower than those in the control group, and the quality of life was higher than that in the control group, with statistical significance (P<0.05). Conclusion Dulagopeptide combined with metformin can effectively improve blood glucose control, body mass index and quality of life in obese type 2 diabetes.

Dulaglutide; Metformin; Obese type 2 diabetes; Blood glucose control; Body Mass Index